Calamos Wealth Management LLC Purchases 38 Shares of Stryker Co. (NYSE:SYK)

Calamos Wealth Management LLC lifted its position in shares of Stryker Co. (NYSE:SYK) by 4.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 960 shares of the medical technology company’s stock after buying an additional 38 shares during the quarter. Calamos Wealth Management LLC’s holdings in Stryker were worth $346,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Capital & Planning LLC boosted its holdings in shares of Stryker by 3.6% during the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock worth $304,000 after buying an additional 29 shares in the last quarter. Alhambra Investment Management LLC lifted its position in shares of Stryker by 1.5% during the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock valued at $719,000 after acquiring an additional 29 shares during the period. Concord Wealth Partners boosted its stake in Stryker by 2.2% during the fourth quarter. Concord Wealth Partners now owns 1,396 shares of the medical technology company’s stock worth $503,000 after acquiring an additional 30 shares in the last quarter. Avestar Capital LLC grew its holdings in Stryker by 1.1% in the third quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock worth $1,065,000 after purchasing an additional 31 shares during the period. Finally, Union Savings Bank raised its holdings in shares of Stryker by 1.0% during the fourth quarter. Union Savings Bank now owns 3,162 shares of the medical technology company’s stock valued at $1,138,000 after purchasing an additional 31 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SYK has been the subject of several research reports. The Goldman Sachs Group raised their target price on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research note on Thursday, January 30th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $370.00 to $445.00 in a research report on Monday, December 2nd. Royal Bank of Canada lifted their price target on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. upped their price objective on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Finally, Truist Financial boosted their target price on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average target price of $419.37.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The disclosure for this sale can be found here. 5.50% of the stock is owned by corporate insiders.

Stryker Price Performance

Shares of NYSE:SYK opened at $392.55 on Wednesday. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company’s 50-day moving average is $376.81 and its 200 day moving average is $363.64. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The company has a market capitalization of $149.65 billion, a P/E ratio of 50.59, a price-to-earnings-growth ratio of 2.78 and a beta of 0.96.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the firm posted $3.46 EPS. On average, equities research analysts forecast that Stryker Co. will post 13.5 earnings per share for the current year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were issued a dividend of $0.84 per share. This is a boost from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend was Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker’s dividend payout ratio is 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.